We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Visible Light-Activated Platinum Compound Shows Potent Anticancer Activity

By LabMedica International staff writers
Posted on 03 Jan 2011
Cancer researchers have identified a photoactivated platinum-based compound that was up to 80 times more potent than other platinum-based chemotherapeutic agents were when tested on cultures of esophageal cancer cells.

Investigators at the University of Warwick (United Kingdom) reported in the November 11, 2010, online edition of the journal Angewandte Chemie that the compound [Pt(N3)2(OH)2(py)2] could be activated by normal visible blue or green light in addition to ultraviolet light.

The compound was readily water soluble and stable in solution. More...
When administered to cultures of esophageal cancer cells and then exposed to low doses of visible blue light, the drug killed 50% of the cancer cells at concentrations as low as 8.4 μmol per liter.

Senior author Dr. Peter Sadler, professor of chemistry at the University of Warwick, said, "This compound could have a significant impact on the effectiveness of future cancer treatments. Light activation provides this compound's massive toxic power and also allows treatment to be targeted much more accurately against cancer cells. The special thing about our complex is that it is not only activated by ultra-violet light, but also by low doses of blue or green light. Light activation generates a powerful cytotoxic compound that has proven to be significantly more effective than treatments such as cisplatin.”

"We believe that photoactivated platinum complexes will make it possible to treat cancers that have previously not reacted to chemotherapy with platinum complexes,” said Dr. Sadler. "Tumors that have developed resistance to conventional platinum drugs could respond to these complexes and with less side-effects.”

Related Links:
University of Warwick



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automatic CLIA Analyzer
Shine i6000
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.